Vanda Pharmaceuticals (VNDA) Competitors $4.43 +0.07 (+1.61%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$4.32 -0.11 (-2.37%) As of 08/14/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VNDA vs. OPK, GERN, ZBIO, MYGN, RIGL, EBS, VSTM, LXRX, XOMA, and CBIOShould you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include OPKO Health (OPK), Geron (GERN), Zenas BioPharma (ZBIO), Myriad Genetics (MYGN), Rigel Pharmaceuticals (RIGL), Emergent Biosolutions (EBS), Verastem (VSTM), Lexicon Pharmaceuticals (LXRX), XOMA Royalty (XOMA), and Crescent Biopharma (CBIO). These companies are all part of the "biotechnology" industry. Vanda Pharmaceuticals vs. Its Competitors OPKO Health Geron Zenas BioPharma Myriad Genetics Rigel Pharmaceuticals Emergent Biosolutions Verastem Lexicon Pharmaceuticals XOMA Royalty Crescent Biopharma Vanda Pharmaceuticals (NASDAQ:VNDA) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment. Is VNDA or OPK more profitable? OPKO Health has a net margin of -26.68% compared to Vanda Pharmaceuticals' net margin of -32.90%. Vanda Pharmaceuticals' return on equity of -12.89% beat OPKO Health's return on equity.Company Net Margins Return on Equity Return on Assets Vanda Pharmaceuticals-32.90% -12.89% -10.47% OPKO Health -26.68%-13.17%-8.28% Does the media refer more to VNDA or OPK? In the previous week, OPKO Health had 1 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 7 mentions for OPKO Health and 6 mentions for Vanda Pharmaceuticals. OPKO Health's average media sentiment score of 0.75 beat Vanda Pharmaceuticals' score of 0.28 indicating that OPKO Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral OPKO Health 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, VNDA or OPK? Vanda Pharmaceuticals has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVanda Pharmaceuticals$198.77M1.32-$18.90M-$1.13-3.92OPKO Health$713.10M1.50-$53.22M-$0.25-5.40 Do insiders & institutionals have more ownership in VNDA or OPK? 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 10.0% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 49.7% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend VNDA or OPK? Vanda Pharmaceuticals presently has a consensus price target of $16.50, suggesting a potential upside of 272.46%. OPKO Health has a consensus price target of $2.75, suggesting a potential upside of 103.70%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than OPKO Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50OPKO Health 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk & volatility, VNDA or OPK? Vanda Pharmaceuticals has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. SummaryOPKO Health beats Vanda Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNDA vs. The Competition Export to ExcelMetricVanda PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$257.63M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-3.9220.4930.2925.74Price / Sales1.32356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book0.548.608.826.15Net Income-$18.90M-$54.65M$3.25B$265.06M7 Day Performance5.48%5.86%3.70%2.60%1 Month Performance-6.93%8.86%5.84%2.83%1 Year Performance-14.31%13.33%29.92%25.58% Vanda Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNDAVanda Pharmaceuticals4.5733 of 5 stars$4.43+1.6%$16.50+272.5%-13.5%$257.63M$198.77M-3.92290News CoverageAnalyst RevisionOPKOPKO Health4.4673 of 5 stars$1.30+4.0%$2.75+111.5%-11.8%$992.23M$713.10M-5.202,997GERNGeron3.3566 of 5 stars$1.36+6.3%$4.19+207.9%-67.3%$816.66M$76.99M-10.46229Analyst RevisionGap UpZBIOZenas BioPharma1.5424 of 5 stars$14.90+1.8%$36.67+146.1%N/A$612.03M$5M-4.20N/ANews CoveragePositive NewsEarnings ReportUpcoming EarningsMYGNMyriad Genetics3.6518 of 5 stars$6.19-2.1%$12.45+101.2%-78.7%$588.04M$837.60M-1.452,700News CoverageRIGLRigel Pharmaceuticals1.8538 of 5 stars$33.46+5.6%$38.20+14.2%+216.5%$568.61M$179.28M6.18160Gap DownHigh Trading VolumeEBSEmergent Biosolutions4.7194 of 5 stars$8.18-4.6%$14.33+75.3%+16.1%$457.22M$1.04B3.342,420News CoverageVSTMVerastem3.1454 of 5 stars$7.70+14.2%$13.50+75.3%+240.5%$414.82M$10K-2.3550Gap UpHigh Trading VolumeLXRXLexicon Pharmaceuticals2.9934 of 5 stars$1.04-3.7%$3.23+210.1%-28.0%$392.47M$31.08M-3.15140XOMAXOMA Royalty4.4822 of 5 stars$27.23+2.8%$69.50+155.2%+20.8%$317.12M$28.49M-23.6810Earnings ReportGap UpCBIOCrescent Biopharma3.975 of 5 stars$12.90+0.4%$25.50+97.7%N/A$251.21M$10K-0.3750News CoverageAnalyst Revision Related Companies and Tools Related Companies OPKO Health Competitors Geron Competitors Zenas BioPharma Competitors Myriad Genetics Competitors Rigel Pharmaceuticals Competitors Emergent Biosolutions Competitors Verastem Competitors Lexicon Pharmaceuticals Competitors XOMA Royalty Competitors Crescent Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VNDA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access